购物车
- 全部删除
- 您的购物车当前为空
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100 μg | ¥ 12,600 | 5日内发货 | |
1 mg | ¥ 84,000 | 5日内发货 |
生物活性 | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
产品描述 | Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
种属 | Human |
表达系统 | HEK293 Cells |
标签 | C-His-Avi |
蛋白编号 | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGACGVGK |
别名 | RASK2,RALD,NS3,NS,MHC,K-RAS4B,K-RAS4A,K-RAS2B,K-RAS2A,KRAS2,KRAS1,K-Ras 2,KRAS,KI-RAS,GTPase Kras,C-K-RAS,CFC2 |
蛋白构建 | Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGACGVGK peptide. Tetramer is assembled by biotinylated monomer and streptavidin. |
蛋白纯度 | > 95% as determined by Tris-Bis PAGE> 90% as determined by HPLC |
内毒素 | < 1 EU/μg by the LAL method. |
缓冲液 | Supplied as 0.22 μm filtered solution in PBS (pH 7.4). |
存储 | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
运输方式 | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
研究背景 | Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.